BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $145,700.00 in Stock

Posted by George Bondi on Nov 6th, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $72.85, for a total transaction of $145,700.00. Following the sale, the chief accounting officer directly owned 120,687 shares in the company, valued at $8,792,047.95. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $74.27 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $60.55 and a 52-week high of $93.42. The firm has a 50 day moving average price of $69.85 and a two-hundred day moving average price of $72.80.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12. The business had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. BridgeBio Pharma’s revenue was up 192.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.95) EPS. On average, equities analysts forecast that BridgeBio Pharma, Inc. will post -2.59 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

Large investors have recently modified their holdings of the company. Hsbc Holdings PLC grew its holdings in BridgeBio Pharma by 139.4% in the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock worth $2,431,000 after purchasing an additional 19,043 shares during the period. Assetmark Inc. increased its stake in BridgeBio Pharma by 423.7% in the first quarter. Assetmark Inc. now owns 20,790 shares of the company’s stock valued at $1,544,000 after purchasing an additional 16,820 shares in the last quarter. EFG International AG bought a new stake in BridgeBio Pharma in the second quarter valued at $6,117,000. Corient Private Wealth LP acquired a new position in shares of BridgeBio Pharma during the second quarter valued at about $1,783,000. Finally, Squarepoint Ops LLC raised its holdings in shares of BridgeBio Pharma by 114.2% during the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock valued at $88,760,000 after purchasing an additional 635,408 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on BBIO shares. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Jefferies Financial Group reissued a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Cantor Fitzgerald restated an “overweight” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Finally, Canaccord Genuity Group lifted their price objective on BridgeBio Pharma from $106.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday. Nineteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average target price of $104.26.

View Our Latest Stock Report on BBIO

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.